



KRAS (G12C) Inhibitor-12 sensitivity

Risk  low  high

1.1e-08

low

high

Risk

20

15

10

5



1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5

1.1e-08

high

Risk

20

15

10

5